Does Venue Type Matter for HIV-Related Risk Behavior in Urban Adolescent and Young Adult Men Who Have Sex With Men?

Citation: Arrington-Sanders R, Fields E, Greenberg L, Henry-Reid L, Stines S, Korelitz J, Kapogiannis B, Ellen J, Boyer CB, and the Adolescent Medicine Trials Network for HIV/AIDS Interventions. Does venue type matter for HIV-related risk behavior in urban adolescent and young adult men who have sex with men? Youth Soc. 2019 Aug;51(8). https://doi.org/10.1177/0044118X17723655

Access full article:

https://journals.sagepub.com/doi/10.1177/0044118X17723655

Venue-based strategies offer effective means of targeting men who have sex with men. Few studies have sought to focus on where younger men congregate and understand risk behaviors that may occur at lower (i.e., community centers) versus higher risk venues. Data from 1,311 young men who have sex with men (YMSM) aged 12- to 24-years-old recruited from publicly accessible venues was used to examine the association between venue type (bar/club, community center, mixed [adjacent to bar/club, including parking lot/alley]) and HIV-related risk factors. YMSM recruited from community venues were more likely than those from bars/clubs to report more partners in last year, receive money in exchange for sex, and to be tested for HIV in prior 6 months, whereas YMSM from mixed-use venues were more likely to have ever received money in exchange for sex, and injected drugs. Community and mixed venues may be key access points for YMSM.

Categories

CRS
Topics

Clinical Trials

A5300/P2003: PHOENIx Feasibility Study

Study of MDR TB Cases and Their Household Contacts: Operational Feasibility to Inform PHOENIx Trial Design

Read More

NWCS 408: Examining Longitudinal Cytokine Profiles in HIV-TB...

Using existing data from A5274 and data obtained from retrospectively testing available biospecimens, we propose the following...

Read More

HPTN083: A Phase 2b/3 Double Blind Safety and Efficacy Study...

HPTN 083 is a study being done to evaluate the efficacy of the long-acting injectable agent, cabotegravir (CAB LA), for...

Read More

A5332: Randomized Trial to Prevent Vascular Events in HIV...

REPRIEVE (A5332) is a large double-blind, randomized, placebo-controlled study of pitavastatin or placebo for about 72 months....

Read More

P1060:  Phase II, parallel, randomized, clinical trials...

A single dose of nevirapine (SD NVP) given to an HIV infected pregnant woman followed by a single dose to her infant has been...

Read More